401 related articles for article (PubMed ID: 29429376)
21. Management of High-grade, Nonmuscle Invasive Urothelial Carcinoma in a Prepubertal Patient With TURBT and Intravesical BCG.
Rague JT; Lee RS
Urology; 2019 Feb; 124():257-259. PubMed ID: 30366046
[TBL] [Abstract][Full Text] [Related]
22. T1G3 bladder cancer--the case for TUR and BCG.
Miller K
Front Radiat Ther Oncol; 2002; 36():147-50. PubMed ID: 11842744
[No Abstract] [Full Text] [Related]
23. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
24. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
25. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
26. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.
DiBianco JM; George AK; Su D; Agarwal PK
Curr Opin Urol; 2015 Sep; 25(5):468-75. PubMed ID: 26125507
[TBL] [Abstract][Full Text] [Related]
27. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
Milowsky MI; Stadler WM; Bajorin DF
BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
[TBL] [Abstract][Full Text] [Related]
28. Localized bladder cancer.
Izawa JI; Grossman HB
Curr Treat Options Oncol; 2000 Dec; 1(5):423-32. PubMed ID: 12057150
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of bladder cancer.
Sharma S; Ksheersagar P; Sharma P
Am Fam Physician; 2009 Oct; 80(7):717-23. PubMed ID: 19817342
[TBL] [Abstract][Full Text] [Related]
30. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
[TBL] [Abstract][Full Text] [Related]
31. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
deVere White RW; Katz MH; Steinberg GD
J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
[No Abstract] [Full Text] [Related]
32. Indications for early cystectomy.
Stein JP
Urology; 2003 Oct; 62(4):591-5. PubMed ID: 14550424
[No Abstract] [Full Text] [Related]
33. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma.
Smaldone MC; Jacobs BL; Smaldone AM; Hrebinko RL
Urology; 2008 Sep; 72(3):613-6. PubMed ID: 18554696
[TBL] [Abstract][Full Text] [Related]
34. [pT1G3 bladder carcinoma: our experience].
Dell'Orto P; Trinchieri A; D'Addezio F; Bernardini P; Mangiarotti B; Del Nero A; Pisani E
Arch Ital Urol Androl; 1996 Feb; 68(1):9-11. PubMed ID: 8664927
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
36. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
37. Controversies in the management of T1 urothelial bladder cancer.
Azzouz H; Cauberg EC; De Reijke TM
Minerva Urol Nefrol; 2011 Dec; 63(4):309-15. PubMed ID: 21996986
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
Achkar T; Parikh RA
Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
[TBL] [Abstract][Full Text] [Related]
39. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
